Sheffield International is marketing and actively pursuing strategic opportunities both for GBP Capital and entities within it's portfolio of companies.

GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They target companies with novel approaches to diagnostics, therapeutics, and medical devices, that will change the face of healthcare innovation in the future. GBP shares the drive and vision of it's portfolio companies to collaborate with them in accelerating growth and building successful business ventures. GBP Capital's existing portfolio is diversified, with investments in therapeutics, medical devices, medical products, and intellectual property, yet there exists a strong synergy amongst the portfolio companies.

GBP Capital is focused on investing in companies with technologies that leverage and build upon these breakthroughs, as well as other major developments taking place within the life-sciences industry. GBP Capital has assembled a core team, whose backgrounds include venture capital, corporate management, investment banking and biotech. We have supplemented our planning and due diligence with a world-class scientific advisory board, comprising of a world renown cancer researcher, one of the world's foremost gene therapy researchers and chair-elect of the academic counsel of the Salk Institute, and the first scientist and entrepreneur to develop and use lentiviral vectors in human trials.



Lentigen Corporation , is a privately held biotechnology company focused on the development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine.  Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Read More.



HyperMed, Inc. is the leader in non-invasive Hyperspectral medical imaging. Their first diagnostic product, OXyVu-1, received diagnostic clearance in November, 2006 for use in assessing patients for poor tissue circulation including those with diabetic foot ulcers, leg pain or other symptoms of poor blood flow.  Hyperspectral Technology (HT), originally developed by the US Department of Defense has recently been applied to the study of physiologic and pathologic changes in animal and human tissue by HyperMed. This technology provides previously unavailable diagnostic information for use in clinical medicine. HyperMed has conducted research in the areas of shock and breast cancer in addition to the studies of patients with diabetic foot ulcers and peripheral arterial disease. HyperMed is at the forefront medical hyperspectral technology, with 7 issued and 19 pending and provisional patents. Read More.